Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2016 Jul 21

PMID 27435752

Citations 24

Authors

A Ke

Z Barter

K Rowland-Yeo

L Almond

Affiliations

Soon will be listed here.

Abstract

In this study, we present efavirenz physiologically based pharmacokinetic (PBPK) model development as an example of our best practice approach that uses a stepwise approach to verify the different components of the model. First, a PBPK model for efavirenz incorporating in vitro and clinical pharmacokinetic (PK) data was developed to predict exposure following multiple dosing (600 mg q.d.). Alfentanil i.v. and p.o. drug-drug interaction (DDI) studies were utilized to evaluate and refine the CYP3A4 induction component in the liver and gut. Next, independent DDI studies with substrates of CYP3A4 (maraviroc, atazanavir, and clarithromycin) and CYP2B6 (bupropion) verified the induction components of the model (area under the curve [AUC] ratios within 1.0-1.7-fold of observed). Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1.7 vs. 1.7 observed). This validated mechanistic model can now be applied in clinical pharmacology studies to prospectively assess both the victim and perpetrator DDI potential of efavirenz.

Citing Articles

PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability.

Ye X, Liu F, Cheng Z, Xie F AAPS J. 2025; 27(2):59.

PMID: 40074933 DOI: 10.1208/s12248-025-01042-9.

A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant.

Adeojo L, Patel R, Sambol N Pharmaceutics. 2024; 16(8).

PMID: 39204395 PMC: 11359785. DOI: 10.3390/pharmaceutics16081050.

Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy.

Coppola P, Butler A, Cole S, Kerwash E Pharmaceutics. 2023; 15(10).

PMID: 37896215 PMC: 10609738. DOI: 10.3390/pharmaceutics15102455.

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models.

Yu Z, Lei Z, Yao X, Wang H, Zhang M, Hou Z Front Pharmacol. 2022; 13:1065130.

PMID: 36582520 PMC: 9792776. DOI: 10.3389/fphar.2022.1065130.

PBPK perspective on alternative CYP3A4 inducers for rifampin.

Chen K, Jones H CPT Pharmacometrics Syst Pharmacol. 2022; 11(12):1543-1546.

PMID: 36146978 PMC: 9755915. DOI: 10.1002/psp4.12864.

References

Wagner C, Pan Y, Hsu V, Sinha V, Zhao P . Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA. Clin Pharmacokinet. 2015; 55(4):475-83. DOI: 10.1007/s40262-015-0330-y. View

Almond L, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O . Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos. 2016; 44(6):821-32. PMC: 4885489. DOI: 10.1124/dmd.115.066845. View

Abel S, Jenkins T, Whitlock L, Ridgway C, Muirhead G . Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008; 65 Suppl 1:38-46. PMC: 2311410. DOI: 10.1111/j.1365-2125.2008.03134.x. View

Kharasch E, Whittington D, Ensign D, Hoffer C, Bedynek P, Campbell S . Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2012; 91(4):673-84. PMC: 3600645. DOI: 10.1038/clpt.2011.276. View

Jones H, Chen Y, Gibson C, Heimbach T, Parrott N, Peters S . Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015; 97(3):247-62. DOI: 10.1002/cpt.37. View

Shou M, Hayashi M, Pan Y, Xu Y, Morrissey K, Xu L . Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab Dispos. 2008; 36(11):2355-70. DOI: 10.1124/dmd.108.020602. View

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A . Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther. 2015; 98(4):406-16. PMC: 4744681. DOI: 10.1002/cpt.156. View

Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid N, Okazaki O . Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica. 2009; 39(11):836-43. DOI: 10.3109/00498250903191427. View

Cho D, Ogburn E, Jones D, Desta Z . Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother. 2011; 55(4):1504-9. PMC: 3067141. DOI: 10.1128/AAC.00883-10. View

10.

Rekic D, Roshammar D, Mukonzo J, Ashton M . In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol. 2011; 71(4):536-43. PMC: 3080641. DOI: 10.1111/j.1365-2125.2010.03883.x. View

11.

Guest E, Aarons L, Houston J, Rostami-Hodjegan A, Galetin A . Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2010; 39(2):170-3. DOI: 10.1124/dmd.110.036103. View

12.

Xu C, Ogburn E, Guo Y, Desta Z . Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos. 2012; 40(4):717-25. PMC: 3310426. DOI: 10.1124/dmd.111.042416. View

13.

Mouly S, Lown K, Kornhauser D, Joseph J, Fiske W, Benedek I . Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002; 72(1):1-9. DOI: 10.1067/mcp.2002.124519. View

14.

Schipani A, Back D, Owen A, Davies G, Khoo S, Siccardi M . Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. Clin Pharmacokinet. 2014; 54(1):107-16. DOI: 10.1007/s40262-014-0184-8. View

15.

Poulin P, Haddad S . Advancing prediction of tissue distribution and volume of distribution of highly lipophilic compounds from a simplified tissue-composition-based model as a mechanistic animal alternative method. J Pharm Sci. 2012; 101(6):2250-61. DOI: 10.1002/jps.23090. View

16.

Sager J, Yu J, Ragueneau-Majlessi I, Isoherranen N . Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos. 2015; 43(11):1823-37. PMC: 4613950. DOI: 10.1124/dmd.115.065920. View

17.

Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D . Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol. 2014; 1:4. PMC: 4230487. DOI: 10.1186/2193-9616-1-4. View

18.

Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A . Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos. 2014; 42(9):1478-84. DOI: 10.1124/dmd.114.058099. View

19.

Tanaka R, Hanabusa H, Kinai E, Hasegawa N, Negishi M, Kato S . Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother. 2007; 52(2):782-5. PMC: 2224777. DOI: 10.1128/AAC.01613-06. View

20.

Balani S, Kauffman L, DeLuna F, Lin J . Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos. 1999; 27(1):41-5. View